Diarylcycloalkyl derivatives, processes for their...

Details Diarylcycloalkyl derivatives, processes for their... Diarylcycloalkyl derivatives, processes for their...

2005-04-26

2005-04-26

Powers, Fiona T. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S236000

Reexamination Certificate

active

06884812

ABSTRACT:
Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I,in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metabolism, of type II diabetes, and of syndrome X.

REFERENCES:
patent: 3174901 (1965-03-01), Sterne
patent: 5190923 (1993-03-01), Vincent et al.
patent: 5814647 (1998-09-01), Urban et al.
patent: 6221633 (2001-04-01), Ertl et al.
patent: 6221897 (2001-04-01), Frick et al.
patent: 6245744 (2001-06-01), Frick et al.
patent: 6342512 (2002-01-01), Kirsch et al.
patent: 6380230 (2002-04-01), Brodin et al.
patent: 6624185 (2003-09-01), Glombik et al.
patent: 20030211421 (2003-11-01), Hanabata et al.
patent: 0 462 884 (1991-12-01), None
patent: P2000-72695 (2000-03-01), None
patent: 9726265 (1997-07-01), None
patent: 9728149 (1997-08-01), None
patent: 9741097 (1997-11-01), None
patent: 9808871 (1998-03-01), None
patent: 9903861 (1999-01-01), None
patent: 9915525 (1999-04-01), None
patent: 0040569 (2000-07-01), None
patent: 0063208 (2000-10-01), None
patent: WO 0064876 (2000-11-01), None
patent: 0064876 (2000-11-01), None
patent: 0064888 (2000-11-01), None
patent: 0066585 (2000-11-01), None
patent: 0071549 (2000-11-01), None
patent: 0078312 (2000-12-01), None
patent: 0109111 (2001-02-01), None
patent: 0183451 (2001-11-01), None
patent: 01-85695 (2001-11-01), None
patent: 0191752 (2001-12-01), None
English language translation of Japanese Patent Application No. P2000-72695.
Beck et al., “The Ontogeny Of Peroxisome-Proliferator-Activated Receptor Gene Expression In The Mouse And Rat,”Proc. R. Soc. Lond. B,247:83-87 (1992).
Okada et al., “Synthesis and Antitumor Activites of Prodrugs of Benzoylphenylureas,” Chem. Pharm. Bull., 42(1), 57-61 (1994).
Lee et al., “Leptin Agonists as a Potential Approach to the Treatment of Obesity,” Drugs of the Future, 26(9), 873-881 (2001).
Salvador et al., “Perspectives in the Therapeutic Use of Leptin,” Expert Opin. Pharmacother., 2(10), 1615-1622 (2001).
Zunft et al., “Carob Pulp Preparation for Treatment of Hypercholesterolemia,” Advanced in Therapy, 18(5), 230-236 (2001).
Motojima, “Peroxisome Proliferator-Activated Receptor (PPAR): Structure, Mechanisms of Activation and Diverse Functions,” Cell Structure and Function, 18, 267-277 (1993).
Tyle, “Iontophoretic Devices for Drug Delivery,” Pharmaceutical Research, 3(6), 318-326 (1986).
Horikoshi et al., “Troglitazone—A Novel Antidiabetic Drug for Treating Insulin Resistance,” DDT, 3(2), 79-88 (1998).
Demetri et al., “Induction of Solid Tumor Differentiation by the Peroxisome Proliferator-Activated Receptor-γ Ligand Troglitazone in Patients with Liposarcoma,” Proc. Natl. Acad. Sci. USA, 96, 3951-3956 (1999).
Elstner et al., “Ligands for Peroxisome Prolierator-Activated Receptor γ and Retinoic Acid Receptor Inhibit Growth and Induce Apoptosis of Human Breast Cancer Cells in vitro and in BNX Mice,” Proc. Natl. Acad. Sci. USA, 95, 8806-8811 (1998).
Sarraf et al., “Differentiation and Reversal of Malignant Changes in Colon Cancer through PPARγ,” Nature Medicine, 4(9), 1046-1052 (1998).
Dunaif et al., “The Insulin-Sensitising Agent Troglitazone Improves Metabolic and Reproductive Abnormalities in the Polycystic Ovary Syndrome,” J. Clin. Endocrinol. Metab., 81(9), 3299-3306 (1996).
Löhrke et al., “Detection and Functional Characterisation of the Transcription Factor Peroxisome Proliferator-Activated Receptor γ in Lutein Cells,” Journal of Endocrinology, 159, 429-439 (1998).
Poynter et al., “Peroxisome Proliferator-Activated Receptor α Activation Modulates Cellular Redox Status, Repress Nuclear Factor-κβ Signaling, and Reduces Inflammatory Cytokine Production in Aging,” J. Biol. Chem., 273(49), 32833-32841 (1998).
Pineda-Torra et al., “Peroxisome Proliferator-Activated Receptor Alpha in Metabolic Disease, Inflammation, Atherosclerosis and Aging,” Curr. Opinion in Lipidology, 10, 151-159 (1999).
Colville-Nash et al., “Inhibition of Inducible Nitric Oxide Synthase by Peroxisome Proliferator-Activated Receptor Agonists: Correlation with Induction of Heme Oxygenase 1,” Journal of Immunology, 161, 978-984 (1998).
Staels et al., “Activation of Human Aortic Smooth-Muscle Cells is Inhibited by PPARα but not by PPARγ Activators,” Nature, 393, 790-793 (1998).
Green, “Receptor-Mediated Mechanisms of Peroxisome Proliferators,” Biochemical Pharmacology, 43(3), 393-401 (1992).
Göttlicher et al., “Fatty acids Activate a Chimera of the Clofibric Acid-Activated Receptor and the Glucocorticoid Receptor,” Proc. Natl. Acad. Sci. USA, 89, 4653-4657 (1992).
Schoonjans, “Peroxisome Proliferator-Activated Receptors, Orphans with Ligands and Functions,” Current Opinion in Lipidology, 8, 159-166 (1997).
Schmidt et al., “Identification of a New Member of the Steroid Hormone Receptor Superfamily that is Activated by a Peroxisome Proliferator and Fatty Acids,” Molecular Endocrinology, 6, 1634-1641 (1992).
Amri et al., “Cloning of a Protein That Mediates Transcriptional Effects of Fatty Acids in Preadipocytes,” J. Biol. Chem., 270(5), 2367-2371 (1995).
Frick et al., “Prevention of the Angiographic Progression of Coronary and Vein-Graft Atherosclerosis by Gemfibrozil After Coronary Bypass Surgery in Men with Low Levels of HDL Cholesterol,” Circulation, 96, 2137-2143 (1997).
De Faire et al., “Retardation of Coronary Atherosclerosis: The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and Other Angiographic Trials,” Cardiovasc. Drugs Ther., 11, 257-263 (1997).
Lehmann et al., “An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ),” J. Biol. Chem., 270(22), 12953-12956 (1995).
Elbrecht et al., “Molecular Cloning, Expression and Characterization of Human Peroxisome Proliferator Activated Receptors γ1 and γ2,” BBRC, 224, 431-437 (1996).
Forman et al., “15-Deoxy-Δ12, 14-Prostaglandin J2Is a Ligand for the Adipocyte Determination Factor PPARγ,” 83 803-812 (1995).
Kliewer et al., “A Prostaglandin J2Metabolite Binds Peroxisome Proliferator-Activated Receptor γ and Promotes Adipocyte Differentiation,” Cell, 83, 813-819 (1995).
Staels et al., “Role of PPAR in the Pharmacological Regulation of Lipoprotein Metabolism, by Fibrates and Thiazolidinediones,” Curr. Pharm. Des., 3(1), 1-14 (1997).
Fruchart et al., “PPARS, Metabolic Disease and Atherosclerosis,” Pharmacol. Research, 44(5), 345-352 (2001).
Kersten et al., “Roles of PPARs in Health and Disease,” Nature, 405, 421-424 (2000).
Pineda-Torra et al., “Peroxisome Proliferator-Activated Receptors: From Transcriptional Control to Clinical Practice,” Curr. Opin. Lipidol., 12, 245-254 (2001).
Asakawa et al., “Cocaine-Amphetamine-Regulated Transcript Influences Energy Metabolism, Anxiety and Gastric Emptying in Mice,” Hormone & Metabolic Research, 33, 554-558 (2001).
Vidal-Puig et al., “Regulation of PPAR γ Gene Expression By Nutrition And Obesity In Rodents,”J. Clin. Invest.,97(11):2553-2561 (1996).

Affiliated with

Also associated with

Rating

Diarylcycloalkyl derivatives, processes for their... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Diarylcycloalkyl derivatives, processes for their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diarylcycloalkyl derivatives, processes for their... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3412508